High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma

Twenty-six patients with acute leukaemia and 14 with high-grade lymphoma received cytosine arabinoside (ara-C) at a twice daily dose of 2 g/m2 administered as a 3-h infusion. Thirty-four patients received 12 doses and six electively received four doses only. Complete remission was achieved in six of...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1984-01, Vol.12 (2), p.90-93
Main Authors: ROHATINER, A, SLEVIN, M. L, DHALIWAL, H. S, MALPAS, J. S, LISTER, T. A
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Alopecia - chemically induced
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Child
Cytarabine - adverse effects
Cytarabine - therapeutic use
Dose-Response Relationship, Drug
Humans
Leukemia - drug therapy
Medical sciences
Middle Aged
Nausea - chemically induced
Neutropenia - chemically induced
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-six patients with acute leukaemia and 14 with high-grade lymphoma received cytosine arabinoside (ara-C) at a twice daily dose of 2 g/m2 administered as a 3-h infusion. Thirty-four patients received 12 doses and six electively received four doses only. Complete remission was achieved in six of seven patients with acute myelogenous leukaemia (AML), one of two evaluable patients with blast crisis of chronic myeloid leukaemia and three of eight patients with acute lymphoblastic leukaemia (ALL). Three further patients with ALL had only minimal bone marrow infiltration after one cycle, toxicity precluding administration of a second. Three patients with AML who received four doses only showed no evidence of response. Four of 14 patients with lymphoma who received 12 doses, entered complete remission. Five additional patients died with minimal residual disease whilst severely neutropenic. A complete and a partial response were seen in two patients with immunoblastic and centrocytic lymphoma respectively who received four doses. These results confirm the activity of high-dose ara-C in patients with AML and suggest that it may also be a potentially useful agent in ALL and high-grade lymphoma, especially as the incidence of CNS toxicity is lower than that reported at higher doses.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00254596